09/07/2017 - 2:41pm

The two drugs had combined brand and generic sales of approximately $893 million, according to data from QunitilesIMS for the 12 months ended July 2017. 

09/05/2017 - 3:59pm
The drug had brand and generic sales of approximately $50.5 million for the 12 months ended June 2017, according to QuntilesIMS data.
09/05/2017 - 3:43pm

Lupin’s generic will be available in 5-, 20- and 40-mg dosage strengths.

09/05/2017 - 3:28pm

The company has named its current global head of drug development and chief medical officer, Dr. Vasant Narasimhan, as CEO, effective Feb. 1, 2018.

09/05/2017 - 2:50pm
The product had an estimated market size of $122.4 million, according to QuintilesIMS data for the 12 months ended June 2017. 
08/29/2017 - 11:29am

A United States appeals court has revived an antitrust lawsuit against four drug makers, alleging that they hamstrung generics for Lipitor and Effexor XR.

08/29/2017 - 9:25am

Researchers found that women with high cholesterol were 45% less likely to develop breast cancer than those without high cholesterol, suggesting their treatment for high cholesterol may be a factor.

08/29/2017 - 8:22am

The patents relative to Restasis are listed in the Orange Book and expire on Aug. 27, 2024, Allergan stated.

08/29/2017 - 7:46am

Cyltezo will be available as 40mg/0.8mL strength pre-filled glass syringes in 2-count cartons.